Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Motif Bio PLC    MTFB   GB00BVVT4H71

MOTIF BIO PLC

(MTFB)
  Report  
Delayed Quote. Delayed London Stock Exchange - 06/25 11:35:27 am
2.725 GBp   -5.38%
06/24Motif Bio Presents New Iclaprim Data at ASM Microbe 2019
GL
06/06Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes
GL
05/31Result of Annual General Meeting
GL
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/19/2019 06/20/2019 06/21/2019 06/24/2019 06/25/2019 Date
3.1(c) 2.84(c) 2.725(c) 2.88(c) 2.725 Last
4 562 218 5 247 238 4 021 332 7 472 163 5 702 801 Volume
+6.90% -8.39% -4.05% +5.69% -5.38% Change
More quotes
Financials (GBP)
Sales 2019 14,9 M
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
Sales 2020 45,1 M
EBIT 2020 -
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0,66x
Capi. / Sales2020 0,22x
Capitalization 9,86 M
More Financials
Company
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The... 
More about the company
Latest news on MOTIF BIO PLC
08:40aMOTIF BIO : Presents New Iclaprim Data at ASM Microbe 2019
AQ
06/24Motif Bio Presents New Iclaprim Data at ASM Microbe 2019
GL
06/08MOTIF BIO : pummelled as FDA asks for more data on antibiotic
AQ
06/06Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meetin..
GL
05/31Result of Annual General Meeting
GL
05/31MOTIF BIO : Result of Annual General Meeting
AQ
05/22MOTIF BIO : AGM Statement
AQ
05/22MOTIF BIO : to Present Iclaprim Data at ASM Microbe 2019
AQ
05/22MOTIF BIO : to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology
AQ
05/21MOTIF BIO : to Present Iclaprim Data at ASM Microbe 2019
AQ
More news
Sector news : Bio Therapeutic Drugs
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
More sector news : Bio Therapeutic Drugs
Chart MOTIF BIO PLC
Duration : Period :
Motif Bio PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOTIF BIO PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Average target price 1,08  GBP
Spread / Average Target 3 650%
Managers
NameTitle
Graham George Lumsden Chief Executive Officer & Executive Director
Richard Cecil Eversfield Morgan Non-Executive Chairman
Jonathan E. Gold Chief Financial Officer & Executive Director
David B. Huang Chief Medical Officer
Rajesh B. Shukla Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MOTIF BIO PLC-90.81%38
GILEAD SCIENCES10.06%80 909
VERTEX PHARMACEUTICALS9.24%42 680
REGENERON PHARMACEUTICALS-16.32%32 744
GENMAB12.51%10 857
SAREPTA THERAPEUTICS INC16.69%8 523